Identification of markers to predict benefit from trastuzumab treatment
Despite the clinical benefit of trastuzumab, some patients do not respond to this therapy. Aims of this study are to identify new predictive biomarkers to distinguish responsive from <i>de novo</i> resistant tumours and to have new insights into the biological characterisation of trastuz...
| Main Author: | |
|---|---|
| Published: |
Open University
2017
|
| Subjects: | |
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.713925 |